Investigational Drug Shows Promise in Diffuse Large B-Cell Lymphoma

A new investigational drug called ADCT-402 that combines a cell-killing compound with a monoclonal antibody shows early promise for patients with diffuse large B-cell lymphoma.

Source: CancerNetwork - November 4, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news